肿瘤细胞治疗研究
英文原题：A 5-Year Update on the Clinical Development of Cancer Cell-Based Vaccines for Glioblastoma Multiforme.
多形性胶质母细胞瘤（GBM）被认为是最具侵袭性的脑癌形式之一，中位生存期为15个月，尽管手术、放疗和化疗已取得进展。
多形性胶质母细胞瘤（GBM）被认为是最具侵袭性的脑癌形式之一，中位生存期为15个月，尽管手术、放疗和化疗已取得进展。免疫抑制的肿瘤微环境和血脑屏障是其预后不良和治疗耐药的主要因素。在过去十年中，基于细胞的疫苗开发取得了显著进展，以增强针对GBM的免疫反应。本综述提供了关于近期涉及各种癌细胞疫苗的临床试验的广泛更新，包括ICT-107、α型-1 DC疫苗等。尽管这些试验已证明在无进展生存期（PFS）和总生存期（OS）方面有潜在改善，但GBM的多样性和免疫抑制性质对一致的治疗成功构成了挑战。我们讨论了这些试验的细节以及疫苗疗效和免疫激活的潜在机制。这些试验的发现强调了个性化免疫治疗方法的重要性，并表明患者分层可以显著推进GBM的临床管理。
Glioblastoma multiforme (GBM) is considered one of the most aggressive forms of brain cancer with a 15-month median survival, despite advancements in surgery, radiotherapy, and chemotherapy. The immune-suppressed tumor microenvironment and the blood-brain barrier are major contributors to its poor prognosis and treatment resistance. In the last decade, significant progress has been made in developing cell-based vaccines to boost immune responses against GBM. This review provides an extensive update on recent clinical trials involving various cancer cell vaccines, including ICT-107, the α-type-1 DC vaccine, and others. Although these trials have demonstrated potential improvements in progression-free survival (PFS) and overall survival (OS), the diverse and immune-suppressed nature of GBM poses challenges for consistent therapeutic success. We discuss the details of these trials along with the potential mechanism of vaccine efficacy and immune activations. The findings of these trials highlight the significance of a personalized immunotherapy approach and suggest that patient stratification could significantly advance the clinical management of GBM.
MEMBER ACCOUNT
登录成功会直接打开下一页。
